Key takeaways
- 6,000 Estimated Type 1 Gaucher patients in the US (MedlinePlus Genetics, NIH)
- 8.8% CYP2D6 ultrarapid metabolizer frequency in Ashkenazi Jewish individuals, excluded from eliglustat (Scott et al., Pharmacogenomics, 2008)
- 45 Adults with Type 1 Gaucher enrolling in Spur Therapeutics' pivotal Phase 3 GALILEO-3 gene therapy trial
- ~2 years Duration patients remained off ERT/SRT after a single avigbagene parvec (FLT201) infusion in Phase 1/2 data
Five approved therapies cover the body, not the brain, and a 45-patient Phase 3 gene therapy trial is racing to replace all five.
Five FDA-approved therapies define Type 1 Gaucher disease treatment: three IV enzyme replacement therapies (imiglucerase/Cerezyme, 1994; velaglucerase alfa/VPRIV, 2010; taliglucerase alfa/Elelyso, 2012) and two oral substrate reduction therapies (eliglustat/Cerdelga, 2014; generic miglustat/Zavesca, 2003). All five are chronic, indefinite regimens; none is disease-modifying and none crosses the blood-brain barrier. Eliglustat, the only first-line oral option, carries a CYP2D6 genotype gate that excludes ultrarapid metabolizers, a phenotype found in 8.8% of Ashkenazi Jewish individuals (Scott et al., Pharmacogenomics, 2008), the same population carrying Gaucher disease's highest mutation frequency. No approved Type 1 therapy addresses CNS risk, despite the established GBA1-Parkinson's link in this same patient population.
An estimated 6,000 people live with Type 1 Gaucher disease in the US, a population payers already fund at roughly $300,000 per patient per year for IV enzyme replacement therapy or a $310,250 WAC for eliglustat. That recurring liability is exactly what a durable, one-time therapy could offset. In Phase 1/2 data, four patients treated with Spur Therapeutics' avigbagene parvec (FLT201) discontinued standard ERT/SRT and remained off treatment for roughly two years. The program has since entered pivotal Phase 3 as GALILEO-3 (~45 adults, first patient dosed July 2026). Payers will demand durability data beyond two years before shifting reimbursement toward a one-time gene-therapy payment model.
The five-drug standard of care, venglustat's Type 3 pivot, and the two gene therapies that tried Type 1.
| Therapy (Sponsor) | Modality & Status | Type 1 Gap Addressed or Left Open |
|---|---|---|
| Eliglustat (Cerdelga) — Sanofi | Approved 2014; oral SRT, CYP2D6-genotype gated | Ultrarapid metabolizers contraindicated; 8.8% of Ashkenazi Jewish patients excluded |
| Venglustat — Sanofi | Phase 3 met primary endpoint; FDA Breakthrough Therapy 2026; filing planned for Type 3 only | CNS-penetrant oral option exists but is not being pursued for Type 1 |
| Avigbagene parvec / FLT201 — Spur Therapeutics | Pivotal Phase 3 GALILEO-3, ~45 GD1 adults, first patient dosed Jul 2026 | Direct challenge to lifelong ERT/SRT; single infusion let patients discontinue standard therapy for ~2 years |
| AVR-RD-02 — AvroBio | Lentiviral ex vivo gene therapy; development halted 2023 | Cautionary precedent: prior Type 1 gene therapy failed on execution, not proven inefficacy |
Sources: Sanofi press releases (Feb/Mar 2026, venglustat LEAP2MONO Phase 3 and FDA Breakthrough Therapy); BioSpace (Jul 2026, Spur Therapeutics GALILEO-3); ClinicalTrials.gov (GALILEO-3, Guard1/AVR-RD-02); Scott SA et al., Pharmacogenomics 2008; Cerdelga FDA Prescribing Information; MedlinePlus Genetics (NIH), Gaucher disease.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Which Type 1 patients are structurally excluded from the only oral therapy today? • A CYP2D6 genotype-gated population sizing that quantifies eliglustat-ineligible patients, with the Ashkenazi Jewish overlap made explicit
- How close is gene therapy to displacing lifelong ERT and SRT in Type 1 Gaucher? • A pivotal-trial timeline for avigbagene parvec (FLT201)/GALILEO-3 against which any new entrant's launch window must be planned
- What reimbursement architecture will payers require before funding a one-time gene therapy over $300K/year chronic ERT? • A payer-posture assessment covering durability-evidence thresholds and outcomes-based contracting precedent
What's inside
-
1 · The Binding Constraint 2 pp
- The CNS gap and CYP2D6 genotype exclusion as the unresolved population
-
2 · The Five-Drug Standard of Care 4 pp
- IV enzyme replacement vs oral substrate reduction
- Where each therapy falls short
-
3 · Venglustat's Type 3 Pivot 3 pp
- Why the CNS-penetrant oral candidate is not pursuing Type 1
-
4 · Gene Therapy — GALILEO-3 and the Prior AvroBio Precedent 4 pp
- Avigbagene parvec (FLT201) Phase 1/2 durability data
- AVR-RD-02's discontinued program as a cautionary marker
-
5 · Payer Posture & Reimbursement Architecture 4 pp
- Durability-evidence thresholds
- One-time payment vs recurring ERT/SRT liability
-
6 · The Assumption Register 2 pp
- Why CYP2D6 ultrarapid-metabolizer frequency is cross-checked against the eliglustat FDA label's own genotype contraindication language
- How AvroBio's 2023 program halt and other gene-therapy competitive status claims are sourced to independent trade press, not company self-description
-
7 · Client Alignment Questions 2 pp
- Whether the client's Type 1 Gaucher program should target the CYP2D6-excluded, largely Ashkenazi Jewish population left without an oral option
- Whether launch timing should be planned against Spur Therapeutics' GALILEO-3 pivotal readout given its head start on durability data
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom brief delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx Gaucher Disease Launch Readiness is built for commercial and market access teams evaluating entry against the five-drug standard of care and the gene therapy pipeline now closing in on it. Custom brief in 72 hours.
- 1. Submit your requestSpecify indication, geography, and launch timeline.
- 2. Scoping callAXLRx analyst confirms pathway assumptions, data sources, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this brief
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
This assessment draws on FDA prescribing information for all five approved Type 1 Gaucher therapies, Sanofi's own 2026 press releases on venglustat, and ClinicalTrials.gov registry entries for the GALILEO-3 and Guard1 gene therapy trials.
CYP2D6 ultrarapid metabolizer frequency is sourced to Scott SA et al. (Pharmacogenomics, 2008) and cross-checked against the eliglustat FDA label's genotype-based contraindication language. Gene therapy competitive status, including AvroBio's 2023 program halt, is sourced to independent trade press rather than company self-description.
- Venglustat's Phase 3 success and Breakthrough Therapy designation confirmed against Sanofi's own press releases, confirmed Type 3-specific rather than Type 1
- FLT201/avigbagene parvec's GALILEO-3 Phase 3 status verified against BioSpace and Spur Therapeutics' own release
- AVR-RD-02's discontinued status verified against independent trade press, not left as an assumption from outdated coverage
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model, and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only: FDA prescribing information for all approved Type 1 therapies, manufacturer disclosures on the investigational agent, and ClinicalTrials.gov registrations. No secondary summaries. Every factual claim is independently verified before inclusion.
Customisation Can I tailor the assessment to my specific question or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. Commission via the intake form to start.